表紙
市場調査レポート

異染性白質ジストロフィー(MLD):世界の治験レビュー

Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014

発行 GlobalData 商品コード 308780
出版日 ページ情報 英文 70 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
異染性白質ジストロフィー(MLD):世界の治験レビュー Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014
出版日: 2014年07月21日 ページ情報: 英文 70 Pages
概要

当レポートでは、異染性白質ジストロフィー(MLD)に関する臨床研究の最新動向について分析し、疾患治療法の概要や、治験における主要国、G7諸国およびE7(新興7カ国)における治験数および被験者採用の状況、地域フェーズ(相)段階別の進行状況、有望なスポンサー、各企業研究機関での研究の進行状況、有望な薬剤の比較といった情報をまとめてお届けします。

イントロダクション

  • 異染性白質ジストロフィー(MLD)
  • 当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • アジア太平洋地域の主要国における治験件数
    • 欧州の主要5ヶ国における治験件数
    • 北米の主要国における治験件数
    • 中東・アフリカの主要国における治験件数
    • 中南米の主要国における治験件数

G7諸国での治験件数:中枢神経系の治験件数に対する異染性白質ジストロフィー(MLD)の治験件数比率

G7諸国における段階別の治験件数

G7諸国での治験件数:進捗状況別

E7諸国での治験件数:中枢神経系の治験件数に対する異染性白質ジストロフィー(MLD)の治験件数比率

E7諸国における段階別の治験件数

段階別の治験件数

  • 進行中の治験:段階別

進捗状況別の治験件数

治験の目標の達成状況

未完了の治験件数 異染性白質ジストロフィー(MLD)

一定期間に採用された被験者

スポンサーの種類別の治験件数

有望なスポンサー

異染性白質ジストロフィー(MLD)治療薬の治験に携わっている主要企業

有望な薬剤

治験のプロファイル

  • 主要企業の治験の概要
    • Shire Plc
    • The Cooper Companies, Inc.
    • GlaxoSmithKline plc
    • Cytomedix, Inc.
  • 代表的な研究機関・病院の治験の概要
    • University of Louisville
    • IRCCS San Raffaele Milano
    • Fondazione San Raffaele del Monte Tabor
    • University of Rostock
    • Fairview University Medical Center
    • New York Medical College
    • Masonic Cancer Center
    • Institut National de la Sante et de la Recherche Medicale
    • National Center for Research Resources
    • Assistance Publique - Hopitaux de Paris

5つの代表的な治験のプロファイル

付録

目次
Product Code: GDHC2247CTIDB

GlobalData's clinical trial report, "Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014" provides data on the Metachromatic Leukodystrophy (MLD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metachromatic Leukodystrophy (MLD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metachromatic Leukodystrophy (MLD). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Metachromatic Leukodystrophy (MLD)
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Metachromatic Leukodystrophy (MLD)
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials
  • Prominent Drugs
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Shire Plc
      • Clinical Trial Overview of Shire Plc
      • The Cooper Companies, Inc.
      • Clinical Trial Overview of The Cooper Companies, Inc.
      • GlaxoSmithKline plc
      • Clinical Trial Overview of GlaxoSmithKline plc
      • Cytomedix, Inc.
      • Clinical Trial Overview of Cytomedix, Inc.
    • Clinical Trial Overview of Top Institutes / Government
      • University of Louisville
      • Clinical Trial Overview of University of Louisville
      • IRCCS San Raffaele Milano
      • Clinical Trial Overview of IRCCS San Raffaele Milano
      • Fondazione San Raffaele del Monte Tabor
      • Clinical Trial Overview of Fondazione San Raffaele del Monte Tabor
      • University of Rostock
      • Clinical Trial Overview of University of Rostock
      • Fairview University Medical Center
      • Clinical Trial Overview of Fairview University Medical Center
      • New York Medical College
      • Clinical Trial Overview of New York Medical College
      • Masonic Cancer Center
      • Clinical Trial Overview of Masonic Cancer Center
      • Institut National de la Sante et de la Recherche Medicale
      • Clinical Trial Overview of Institut National de la Sante et de la Recherche Medicale
      • National Center for Research Resources
      • Clinical Trial Overview of National Center for Research Resources
      • Assistance Publique - Hopitaux de Paris
      • Clinical Trial Overview of Assistance Publique - Hopitaux de Paris
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Region, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Central and South America, Top Countries, 2014*
  • Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, G7 Countries (%), 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, E7 Countries (%), 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Metachromatic Leukodystrophy (MLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Shire Plc, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by The Cooper Companies, Inc., 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Cytomedix, Inc., 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Louisville, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by IRCCS San Raffaele Milano, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fondazione San Raffaele del Monte Tabor, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Rostock, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Fairview University Medical Center, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by New York Medical College, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Masonic Cancer Center, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Institut National de la Sante et de la Recherche Medicale, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by National Center for Research Resources, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials Market, Global, Clinical Trials by Assistance Publique - Hopitaux de Paris, 2014*

List of Figures

  • Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Asia-Pacific, Top Countries (%), 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2014*
  • Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, G7 Countries (%), 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Metachromatic Leukodystrophy (MLD) to Central Nervous System Clinical Trials, E7 Countries (%), 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Metachromatic Leukodystrophy (MLD) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Metachromatic Leukodystrophy (MLD) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top